For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Oxybutynin - Overactive bladder (adults)
PAD Profile : Oxybutynin - Overactive bladder (adults)
Traffic Light Status
Status 1 of 2.
- Patches
Status 2 of 2.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Darifenacin hydrobromide
- Flavoxate hydrochloride
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Fesoterodine fumarate
- Trospium chloride
- Tolterodine
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.
Oxybutynin immediate-release and modified-release tablets are non-formulary. A switch from oxybutinin tablets to solifenacin is recommended (where appropriate).
Patients with swallowing difficulties
Solifenacin oral SUSPENSION 1mg/ml sugar free is the preferred treatment option.
Oxybutynin patches should be reserved for patients in whom an oral route is not suitable.
See Selection Tool for locally agreed OAB treatment options